Economic evaluation of the FIBROWALK multicomponent intervention in online and outdoor formats for fibromyalgia (The On & Out Study)
Fibromyalgia (FM) is a chronic condition with substantial healthcare and societal costs. Although multicomponent interventions are widely available, evidence of their economic impact remains scarce. This study evaluated the cost-utility and cost-effectiveness of the FIBROWALK intervention in online...
| Autores: | , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2025 |
| País: | España |
| Institución: | Universitat Autònoma de Barcelona |
| Repositorio: | Dipòsit Digital de Documents de la UAB |
| Idioma: | inglés |
| OAI Identifier: | oai:ddd.uab.cat:319152 |
| Acceso en línea: | https://ddd.uab.cat/record/319152 https://dx.doi.org/urn:doi:10.1016/j.jpain.2025.105515 |
| Access Level: | acceso embargado |
| Palabra clave: | Fibromyalgia Multicomponent intervention FIBROWALK Cost-utility Costeffectiveness |
| Sumario: | Fibromyalgia (FM) is a chronic condition with substantial healthcare and societal costs. Although multicomponent interventions are widely available, evidence of their economic impact remains scarce. This study evaluated the cost-utility and cost-effectiveness of the FIBROWALK intervention in online (FIBRO-On) and outdoor (FIBRO-Out) formats, compared to treatment as usual (TAU), for individuals with FM. An economic evaluation (n = 225) was conducted over six months from government (total costs) and healthcare (direct costs) perspectives. The follow-up assessment was conducted six months after baseline, which corresponds to three months after the end of the 12-week intervention. Direct and indirect costs were collected through the Client Service Receipt Inventory. Cost-utility was assessed with Quality Adjusted Life Years (QALYs) and cost-effectiveness with the Revised Fibromyalgia Impact Questionnaire (FIQR). FIBRO-On was superior to TAU in reducing specialized healthcare costs (Cohen's d = 0.71), improving perceived health (d = 0.50), and reducing FM severity (d = 0.56). Compared to FIBRO-Out, FIBRO-On also reduced healthcare costs and improved both QALYs and FIQR scores. In contrast, FIBRO-Out led to significantly higher costs than TAU and showed no significant benefit in QALYs or FIQR scores. Across intentionto-treat, complete case, and per-protocol analyses, FIBRO-On was also the more favorable intervention, particularly in comparison to FIBRO-Out. These findings suggest that FIBROOn may be a cost-effective intervention for managing FM compared to TAU or FIBRO-Out. Furthermore, they underscore the potential benefits of exploring digital interventions such as FIBRO-On to improve accessibility and promote efficient use of healthcare resources to manage FM. |
|---|